Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Knopp Biosciences presents positive preclinical data for neonatal epilepsy drug candidate KB-3061

May 28, 2019

Phase III study of Lyrica in PGTC seizures fails to meet primary endpoint

May 27, 2019

FDA approves Zolgensma for spinal muscular atrophy

May 27, 2019

Location, location, location: Looking between the lines leads to neurofibromatosis insight

May 27, 2019

NRD.E1 demonstrates promising safety and efficacy in proof-of-concept study

May 27, 2019

Long-term data presented from FORWARD-2 study of ALKS-5461

May 27, 2019

Cyxone to seek clearance for phase I study of MS drug candidate T20K

May 24, 2019

APRINOIA Therapeutics awarded Michael J. Fox Foundation grant for Parkinson's research

May 24, 2019

Injection of CSF from multiple sclerosis patients generates mouse model of cerebellar dysfunction

May 24, 2019

Glutamate receptor predicts suicidality in PTSD

May 24, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.